98%
921
2 minutes
20
Objective: To explore the best ablative margin (AM) for single hepatocellular carcinoma (HCC) patients with image-guided percutaneous thermal ablation (IPTA) based on MRI-MRI fusion imaging, and to develop and validate a local tumor progression (LTP) predictive model based on the recommended AM.
Methods: Between March 2014 and August 2019, 444 treatment-naïve patients with single HCC (diameter ≤3 cm) who underwent IPTA as first-line treatment from three hospitals were included, which were randomly divided into training (n= 296) and validation (n = 148) cohorts. We measured the ablative margin (AM) by MRI-MRI fusion imaging based on pre-ablation and post-ablation images. Then, we followed up their LPT and verified the optimal AM. Risk factors related to LTP were explored through Cox regression models, the nomogram was developed to predict the LTP risk base on the risk factors, and subsequently validated. The predictive performance and discrimination were assessed and compared with conventional indices.
Results: The median follow-up was 19.9 months (95% CI 18.0-21.8) for the entire cohort. The results revealed that the tumor size (HR: 2.16; 95% CI 1.25-3.72; P = 0.003) and AM (HR: 0.72; 95% CI, 0.61-0.85; P < 0.001) were independent prognostic factors for LTP. The AM had a pronounced nonlinear impact on LTP, and a cut-off value of 5-mm was optimal. We developed and validated an LTP predictive model based on the linear tumor size and nonlinear AM. The model showed good predictive accuracy and discrimination (training set, concordance index [C-index] of 0.751; validation set, C-index of 0.756) and outperformed other conventional indices.
Conclusion: The 5-mm AM is recommended for the best IPTA candidates with single HCC (diameter ≤3 cm). We provided an LTP predictive model that exhibited adequate performance for individualized prediction and risk stratification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604653 | PMC |
http://dx.doi.org/10.2147/JHC.S330746 | DOI Listing |
Cancer Treat Res Commun
August 2025
Department of Gastrointestinal Surgery, Aalborg University Hospital, Denmark; Department of Clinical Medicine, Aalborg University, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Denmark.
Background: Irreversible electroporation (IRE) is a novel anticancer ablative treatment, which has been proposed to enhance the efficacy of chemotherapy in the periphery of the ablated area by capturing chemotherapy intracellularly. The aim of the current trial was to characterize the ablated lesion to get spatial information about the distribution of captured chemotherapy and in extension to assess the a priori probability of efficacy for the combined intervention.
Methods: IRE ablations were performed in five pigs with or without concurrent intravenous bleomycin and gadolinium contrast injection.
Front Oncol
August 2025
Department of Spinal Surgery, No. 1 Orthopedics Hospital of Chengdu, Chengdu, China.
Primary bone tumours remain among the most challenging indications in radiation oncology-not because of anatomical size or distribution, but because curative intent demands ablative dosing alongside stringent normal-tissue preservation. Over the past decade, the therapeutic landscape has shifted markedly. Proton and carbon-ion centres now report durable local control with acceptable late toxicity in unresectable sarcomas.
View Article and Find Full Text PDFDiagn Pathol
August 2025
Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, China.
Background: Perivascular epithelioid cell tumor (PEComa) of the pancreas is a rare tumor of pancreatic mesenchymal origin with malignant potential. Critical to appropriate clinical management is determining whether the tumor is benign or malignant. Because of its rarity, morphologic and histologic characteristics and limited patient follow-up of pancreatic PEComa have precluded precise definition of malignancy.
View Article and Find Full Text PDFMaterials (Basel)
July 2025
Space System Engineering Section, Space Engineering, Faculty of Aerospace Engineering, TU Delft, Kluyverweg 1, 2629 HS Delft, The Netherlands.
This study presents a simulation-based damage modeling and fatigue risk assessment of a reusable ceramic matrix composite thruster designed for short-duration, green bipropellant propulsion systems. The thruster is constructed from a fiber-reinforced ultra-high temperature ceramic matrix composite composed of zirconium diboride, silicon carbide, and carbon fibers. Time-resolved thermal and structural simulations are conducted on a validated thruster geometry to characterize the severity of early-stage thermal shock, stress buildup, and potential degradation pathways.
View Article and Find Full Text PDFCancers (Basel)
August 2025
Harvard Medical School, Boston, MA 02115, USA.
Histotripsy is a novel, noninvasive, non-thermal technology invented in 2004 for the precise destruction of biologic tissue. It offers a powerful alternative to more conventional thermal or surgical interventions. Using short-pulse, low-duty cycle ultrasonic waves, histotripsy creates cavitation bubble clouds that selectively and precisely destroy targeted tissue in a predefined volume while sparing critical structures like bile ducts, ureters, and blood vessels.
View Article and Find Full Text PDF